COVID-19 Update #134 6/9/2022

COVID-19 Vaccines
 
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21-0 with one abstention to recommend an EUA for Novavax’s two-dose COVID-19 vaccine for patients 18 years and older. An FDA review and the discussion by the VRBPAC expressed concern about myocarditis, although the adverse effect appears to be rare. 
 
Moderna announced interim data from a Phase II/III trial where an investigational bivalent COVID-19 vaccine containing a combination of the original vaccine and an Omicron variant specific vaccine elicited higher antibody levels for both the original SAR-COV-2 virus and the Omicron variant.